Hubert S. Chou

633 total citations
12 papers, 453 citations indexed

About

Hubert S. Chou is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Hubert S. Chou has authored 12 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Hubert S. Chou's work include Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (4 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers). Hubert S. Chou is often cited by papers focused on Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (4 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers). Hubert S. Chou collaborates with scholars based in United States, United Kingdom and Japan. Hubert S. Chou's co-authors include Philip Zeitler, Kenneth C. Copeland, Elizabeth Sellers, Jeff Powell, Terry T.‐K. Huang, Erika Gebel Berg, Tamara S. Hannon, William V. Tamborlane, Jane L. Chiang and Kristen J. Nadeau and has published in prestigious journals such as Diabetes Care, Diabetes Obesity and Metabolism and Current Medical Research and Opinion.

In The Last Decade

Hubert S. Chou

12 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hubert S. Chou United States 9 325 117 100 95 55 12 453
Barrie Chubb United Kingdom 17 517 1.6× 115 1.0× 139 1.4× 78 0.8× 42 0.8× 38 649
Jennal Johnson United States 11 316 1.0× 74 0.6× 74 0.7× 71 0.7× 19 0.3× 28 418
Weigang Zhao China 13 241 0.7× 87 0.7× 83 0.8× 54 0.6× 43 0.8× 55 547
Gregory E. Peterson United States 7 358 1.1× 127 1.1× 48 0.5× 88 0.9× 47 0.9× 8 471
Marloes P. van der Aa Netherlands 10 218 0.7× 62 0.5× 52 0.5× 67 0.7× 122 2.2× 11 407
Doron Schneider United States 12 216 0.7× 107 0.9× 67 0.7× 68 0.7× 24 0.4× 24 412
Mike Baxter United Kingdom 11 258 0.8× 119 1.0× 48 0.5× 70 0.7× 35 0.6× 23 377
Ulagamathesan Venkatesan India 12 194 0.6× 49 0.4× 38 0.4× 68 0.7× 35 0.6× 46 399
V. Tony Chetty Canada 11 139 0.4× 104 0.9× 56 0.6× 60 0.6× 61 1.1× 15 440
G Forlani Italy 14 178 0.5× 56 0.5× 72 0.7× 43 0.5× 77 1.4× 22 443

Countries citing papers authored by Hubert S. Chou

Since Specialization
Citations

This map shows the geographic impact of Hubert S. Chou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hubert S. Chou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hubert S. Chou more than expected).

Fields of papers citing papers by Hubert S. Chou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hubert S. Chou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hubert S. Chou. The network helps show where Hubert S. Chou may publish in the future.

Co-authorship network of co-authors of Hubert S. Chou

This figure shows the co-authorship network connecting the top 25 collaborators of Hubert S. Chou. A scholar is included among the top collaborators of Hubert S. Chou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hubert S. Chou. Hubert S. Chou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Ito, Takashi, Tharin Limsakun, Hamim Zahir, et al.. (2022). Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor. Clinical and Translational Science. 15(4). 967–980. 3 indexed citations
2.
3.
Nadeau, Kristen J., Barbara J. Anderson, Erika Gebel Berg, et al.. (2016). Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. Diabetes Care. 39(9). 1635–1642. 262 indexed citations
4.
Zeitler, Philip, Hubert S. Chou, Kenneth C. Copeland, & Mitchell E. Geffner. (2015). Clinical Trials in Youth-Onset Type 2 Diabetes: Needs, Barriers, and Options. Current Diabetes Reports. 15(5). 28–28. 23 indexed citations
5.
Rosenson, Robert S., et al.. (2014). Effect of Colesevelam HCl Monotherapy on Lipid Particles in Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy. 28(3). 229–236. 5 indexed citations
6.
Rosenstock, Julio, et al.. (2014). Efficacy and Safety of Colesevelam in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus. Hormone and Metabolic Research. 46(13). 943–949. 8 indexed citations
7.
Rosenstock, Julio, et al.. (2013). The Glucose and Lipid Effects of Colesevelam as Monotherapy in Drug-naïve Type 2 Diabetes. Hormone and Metabolic Research. 46(5). 348–353. 11 indexed citations
8.
Henry, Robert R., Vanita R. Aroda, Sunder Mudaliar, et al.. (2011). Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 14(1). 40–46. 21 indexed citations
9.
Truitt, Kenneth E., Ronald Goldberg, Julio Rosenstock, et al.. (2010). A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Current Medical Research and Opinion. 26(6). 1321–1331. 9 indexed citations
10.
Rosenstock, Julio, Hubert S. Chou, S. Matthäei, D. Seidel, & A. Hamann. (2008). Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. Diabetes Obesity and Metabolism. 10(10). 862–873. 3 indexed citations
11.
Chou, Hubert S., et al.. (2007). Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obesity and Metabolism. 10(8). 626–637. 25 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barrie Chubb Breakdown of academic impact, for papers by Jennal Johnson Breakdown of academic impact, for papers by Weigang Zhao Breakdown of academic impact, for papers by Gregory E. Peterson Breakdown of academic impact, for papers by Marloes P. van der Aa Breakdown of academic impact, for papers by Doron Schneider Breakdown of academic impact, for papers by Mike Baxter Breakdown of academic impact, for papers by Ulagamathesan Venkatesan Breakdown of academic impact, for papers by V. Tony Chetty Breakdown of academic impact, for papers by G Forlani
Rankless by CCL
2026